Cargando…

Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder

BACKGROUND: Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). OBJECTIVE: We investigated the use of cardiac [(123)I]meta-iodo-benzyl-guanidine scintigraphy ([(123)I]MIBG) and olfactory testing— in comparison to [...

Descripción completa

Detalles Bibliográficos
Autores principales: Janzen, Annette, Vadasz, David, Booij, Jan, Luster, Markus, Librizzi, Damiano, Henrich, Martin T., Timmermann, Lars, Habibi, Mahboubeh, Sittig, Elisabeth, Mayer, Geert, Geibl, Fanni, Oertel, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535565/
https://www.ncbi.nlm.nih.gov/pubmed/35754288
http://dx.doi.org/10.3233/JPD-223201
_version_ 1784802798576074752
author Janzen, Annette
Vadasz, David
Booij, Jan
Luster, Markus
Librizzi, Damiano
Henrich, Martin T.
Timmermann, Lars
Habibi, Mahboubeh
Sittig, Elisabeth
Mayer, Geert
Geibl, Fanni
Oertel, Wolfgang
author_facet Janzen, Annette
Vadasz, David
Booij, Jan
Luster, Markus
Librizzi, Damiano
Henrich, Martin T.
Timmermann, Lars
Habibi, Mahboubeh
Sittig, Elisabeth
Mayer, Geert
Geibl, Fanni
Oertel, Wolfgang
author_sort Janzen, Annette
collection PubMed
description BACKGROUND: Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). OBJECTIVE: We investigated the use of cardiac [(123)I]meta-iodo-benzyl-guanidine scintigraphy ([(123)I]MIBG) and olfactory testing— in comparison to [(123)I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single photon emission computed tomography ([(123)I]FP-CIT-SPECT)— for identifying iRBD patients as prodromal phenotype of PD/DLB. METHODS: 37 RBD subjects underwent cardiac [(123)I]MIBG and brain [(123)I]FP-CIT-SPECT at baseline. Olfactory (Sniffin’ Sticks), cognitive and motor functions were tested annually for ∼4 years. RESULTS: 29/37 (78.4%) subjects had a pathological [(123)I]MIBG, of whom 86.2% (25/29) presented at least a moderate hyposmia at baseline (threshold/discrimination/identification-(TDI-)score ≤25). 20/37 (54.1%) subjects had a pathological [(123)I]FP-CIT-SPECT, always combined with a pathological [(123)I]MIBG. In subjects with pathological [(123)I]MIBG, olfactory function worsened (mainly due to threshold and discrimination subscores) from baseline to follow-up (p = 0.005). Olfaction was more impaired in subjects with pathological [(123)I]MIBG compared to those with normal [(123)I]MIBG at baseline (p = 0.001) and follow-up (p < 0.001). UPDRS-III scores increased in subjects with both pathological [(123)I]MIBG and [(123)I]FP-CIT-SPECT. In this group, seven subjects phenoconverted to PD, all— except for one— presented with at least moderate hyposmia at baseline. CONCLUSION: A combination of the biomarkers “pathological [(123)I]MIBG” and “hyposmia” likely identifies iRBD patients in an early prodromal stage of PD/DLB, i.e., before nigrostriatal degeneration is visualized. One-third of the subjects with pathological [(123)I]MIBG had a normal [(123)I]FP-CIT-SPECT. Noteworthy, in iRBD subjects with pathological [(123)I]MIBG, olfactory impairment is progressive independent of the [(123)I]FP-CIT-SPECT status.
format Online
Article
Text
id pubmed-9535565
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-95355652022-10-20 Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder Janzen, Annette Vadasz, David Booij, Jan Luster, Markus Librizzi, Damiano Henrich, Martin T. Timmermann, Lars Habibi, Mahboubeh Sittig, Elisabeth Mayer, Geert Geibl, Fanni Oertel, Wolfgang J Parkinsons Dis Research Report BACKGROUND: Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). OBJECTIVE: We investigated the use of cardiac [(123)I]meta-iodo-benzyl-guanidine scintigraphy ([(123)I]MIBG) and olfactory testing— in comparison to [(123)I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single photon emission computed tomography ([(123)I]FP-CIT-SPECT)— for identifying iRBD patients as prodromal phenotype of PD/DLB. METHODS: 37 RBD subjects underwent cardiac [(123)I]MIBG and brain [(123)I]FP-CIT-SPECT at baseline. Olfactory (Sniffin’ Sticks), cognitive and motor functions were tested annually for ∼4 years. RESULTS: 29/37 (78.4%) subjects had a pathological [(123)I]MIBG, of whom 86.2% (25/29) presented at least a moderate hyposmia at baseline (threshold/discrimination/identification-(TDI-)score ≤25). 20/37 (54.1%) subjects had a pathological [(123)I]FP-CIT-SPECT, always combined with a pathological [(123)I]MIBG. In subjects with pathological [(123)I]MIBG, olfactory function worsened (mainly due to threshold and discrimination subscores) from baseline to follow-up (p = 0.005). Olfaction was more impaired in subjects with pathological [(123)I]MIBG compared to those with normal [(123)I]MIBG at baseline (p = 0.001) and follow-up (p < 0.001). UPDRS-III scores increased in subjects with both pathological [(123)I]MIBG and [(123)I]FP-CIT-SPECT. In this group, seven subjects phenoconverted to PD, all— except for one— presented with at least moderate hyposmia at baseline. CONCLUSION: A combination of the biomarkers “pathological [(123)I]MIBG” and “hyposmia” likely identifies iRBD patients in an early prodromal stage of PD/DLB, i.e., before nigrostriatal degeneration is visualized. One-third of the subjects with pathological [(123)I]MIBG had a normal [(123)I]FP-CIT-SPECT. Noteworthy, in iRBD subjects with pathological [(123)I]MIBG, olfactory impairment is progressive independent of the [(123)I]FP-CIT-SPECT status. IOS Press 2022-09-02 /pmc/articles/PMC9535565/ /pubmed/35754288 http://dx.doi.org/10.3233/JPD-223201 Text en © 2022 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Report
Janzen, Annette
Vadasz, David
Booij, Jan
Luster, Markus
Librizzi, Damiano
Henrich, Martin T.
Timmermann, Lars
Habibi, Mahboubeh
Sittig, Elisabeth
Mayer, Geert
Geibl, Fanni
Oertel, Wolfgang
Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder
title Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder
title_full Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder
title_fullStr Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder
title_full_unstemmed Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder
title_short Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder
title_sort progressive olfactory impairment and cardiac sympathetic denervation in rem sleep behavior disorder
topic Research Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535565/
https://www.ncbi.nlm.nih.gov/pubmed/35754288
http://dx.doi.org/10.3233/JPD-223201
work_keys_str_mv AT janzenannette progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder
AT vadaszdavid progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder
AT booijjan progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder
AT lustermarkus progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder
AT librizzidamiano progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder
AT henrichmartint progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder
AT timmermannlars progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder
AT habibimahboubeh progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder
AT sittigelisabeth progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder
AT mayergeert progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder
AT geiblfanni progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder
AT oertelwolfgang progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder